nav menu
close nav
background
background

NEWS

16 October 2021

Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452

29 September 2021

The Next COVID Challenge: Building an Arsenal of Vaccines

7 September 2021

Second-generation vaccines offer a chance to correct flaws in early vaccination campaigns

31 August 2021

More accessible Covid-19 vaccines and community engagement key for rural areas

30 August 2021

In the pipeline: What the next wave of COVID-19 vaccines could look like

20 August 2021

Second Wave of COVID-19 Vaccines Could Resolve Vaccine Inequity

5 August 2021

Akston Biosciences Doses First Subjects in Phase II Clinical Trial of Second-Generation Protein Subunit COVID-19 Vaccine

2 August 2021

mRNA deals will not solve Africa’s vaccine shortfall, but the second generation of vaccines may

21 July 2021

Could second-generation vaccines accelerate Africa’s slow immunisation drive?

21 July 2021

Akston Biosciences Announces Commercial Supply Agreement of Seppic’s Adjuvant to Formulate Akston Shelf-stable COVID-19 Vaccine at Global Scale